Skip to content
Screener

Exelixis EXEL Business Segments — Total revenues

Similar metrics at other companies

nCino, Inc. logo
NCNOReportable Segment — Total revenues
$159.41M+10.6%
BJ's Wholesale Club Holdings, Inc. logo
BJReportable Segment — Total revenues
$5.66B+9.9%
Calix logo
CALXReportable Segment — Total revenues
$293.33M+21.3%
CuriosityStream logo
CURIReportable Segment — Total revenues
$15.16M+0.5%
comScore logo
SCORReportable Segment — Total revenues
$85.32M-0.5%
Neurocrine Biosciences logo
NBIXReportable Segment — Total revenues
$814.5M+42.2%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues$628,690$568,261$1,239,502$1,123,708
Less:
Cost of goods sold20,65719,47040,61038,642
Drug discovery18,25221,35737,72839,610
Development150,522134,159286,237287,376
Selling, general, and administrative127,413112,931250,283233,706
Other segment items(1)63,37866,718124,616124,134
Interest income(14,210)(16,789)(30,337)(35,865)

Item 1. Financial Statements.

FAQ

What is Exelixis's business segments — total revenues?
Exelixis (EXEL) reported business segments — total revenues of $628.69M in Q2 2026.
How has Exelixis's business segments — total revenues changed year-over-year?
Exelixis's business segments — total revenues increased by 10.6% year-over-year, from $568.26M to $628.69M.
What is the long-term trend for Exelixis's business segments — total revenues?
Over 3 years (2022 to 2025), Exelixis's business segments — total revenues has grown at a 12.9% compound annual growth rate (CAGR), from $1.61B to $2.32B.
What does business segments — total revenues mean?
Represents the total gross income generated by the company's primary business segment through the sale of pharmaceutical products and licensing agreements. This metric reflects the market demand for the company's oncology portfolio and its ability to monetize commercialized therapies.

Ask your AI about Exelixis's business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude